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yrs. Patients were included only if alive and in remission Sep. 
2002. Lansk T and Karnofsky scores (LK-score) as well as GvHD 
were evaluated prospectively just prior to conditioning and follow- 
ing the transplant at day 100, ly and at latest follow-up at least 
five yrs post transplant. A total of 120 patients met the inclusion 
criteria of these 56 patients (79% leukemia orMDS) survived long 
term but 4 pts were lost to follow-up. Donors consisted of HLA- 
id sib 54%, other faro. donors 15% and matched unrelated 31%. 
Results: Median LK scores were: 93% (range: 100-50%) before 
SCT, 88% (range: 100-30) day 100 (before vs. dl00 p=0.029), 
94% (range: 100-50) at ly (dl00 vs. ly: p<0.001) and 97% (range: 
100-80%) +5 yrs (ly vs. +5yrs p=0.006) after SCT. ChGvHD was 
present in 42% at ly and in 15% at +Syrs of long term smwiving 
patient. Patients transplanted with alternative donors experienced 
significant decreased LK scores: dl00 (p<0.001), ly (p=0.022) and 
+5yrs (p=0.003) compared to patients transplanted with HLA-id 
donors. Patients with chronic GvHD at ly and +5yrs had signifi- 
cantly decreased LK-score (p=0.046 and p=0.003). Conclusion: 
ChGvHD had a major impact on LK-scores. However, the major- 
ity of long term surviving young patients had a very good per- 
formance five or more years after allo SCT. Compared to pre- 
transplant 91% had an unchanged or increased LK-score. 
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QUALITY OF LIFE (QOL) AFTER ALLOGENEIC STEM CELL TRANSPLAN- 
TATION: PROSPECTIVE STUDY OF PREDICTORS OF IMPAIRED QOL 
Oka~noto, S.: Nshihira, M.; ~/Iori, T.; H?rooka, }~: Jr~ashiT~a, T.; 
Kiuchi, K.; S,~i~nura, )~; Zakeno, H.; Kondo, S. Division of Hem, atology, 
Keio University School of MedMne, Toleyo, Japan. 
The improvement in life expectancy following SCT has resulted 
in growing interests in conducting research on their QOL. This 
study prospectively measured the QOL of relatively large group of 
survivors after SCT, and assessed the factors that negatively 
affected their QOL. A total of 111 patients with malignant and 
non-malignant hematologic disorders who underwent SCT at 
Keio University Hospital from 1995 to January 2001 and survived 
without disease more than 6 months were included in this study. 
QOL was assessed by using Medical Outcome Survey-short Form 
36(SF-36), HAD-A, D (Hospital anxiety and depression scale), 
and BHS (Beck hopelessness core) starting at 6 months after 
SCT and every 6 months thereafter. The time since transplant has 
a significant influence on QOL after SCT measured by SF-36. 
The scores of both physical and social domains lower than the 
average of age-adjusted general population until one year after 
SCT except for vitality and mental health. The scores of all 
domains except for role physical and social functioning returned 
to normal by 1.5 years, and those who had survived beyond 2.5 
years are Indistinguishable from age-adjusted normal population 
and significantly better in certain domains of QOL. The scores of 
HAD and BHS remained basically unchanged after SCT. By mul- 
tiivariate analysis, those who were not married at the time of 
transplant had a significantly lower score in bodily pain, and 
women who were not working as a house wife had a significantly 
lower score of vitality, role emotional and mental health at one 
year after SCT. At 2 years after SCT, non-family member as a 
caregiver was a significant risk factor of lower scores in physical 
functioning and role physical domains. Male gender, male gender 
and family conflicts were also identified as significant risk factors 
of low scores of bodily pain and general heaith, respectively. We 
think that these data are useful to assist ransplant teams in devel- 
oping strategies to explore the nursing'intervention t  improve 
the QOL after SCT. Future study with more patients, longer fol- 
low-up, and data collecting at each t~oint after SCT is warranted 
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SYSTEMATIC REVIEW OF THE LITERATURE REGARDING FAMILY 
IMPACT WHEN AN ADULT MEMBER EXPERIENCES BONE MARROW 
TRANSPLANTATION 
Y01mg, L.K. N ,  rsi~zg, MSOE, Milv:aukee, WI; University OF Wis- 
consi~z-Madison, Madison, I/VI. 
Seventy-Five percent of bone marrow transplantions are per- 
formed on individuals 21-50 years of age, Bone/Blood cell trans- 
plantations are themselves an intensive, poissibly life threatening 
event. Best practice informs us that financial burden, extended 
absence from the family, role changes, care giver burden and 
stress are part of the impact of transplantation families. It was 
the purpose of this systematic review of literature to sunnnarize 
evidence regarding impact on families when an adult member 
receives bone marrow transplanatation. Twelve research studies 
were identified after a systematic, in-depth search was conducted. 
Four subgroups of studies included studies which addressed family 
functioning and psychological status; quality of life; family emo- 
tional expression, personality, anxiety and deprssion; and lastly, 
family caregiving. The studies varied in design. None were ran- 
domized controlled trials. Studies were from three countries. No 
study examined family interventions. Bone marrow transplanta- 
tion of adult patients indeed impacts family. In relation to psycho- 
logical well being, quality of life, family functioning and caregiv- 
ing. Children in the family expereince the impact of 
transplantation differently at differnt developmental stages. Cou- 
ples experienced martial dissatisfaction and sexual dysfunction 
although overall quality of life was satisfying. A sense of filturc 
emerged at twelve months post transplant for the falnily unit. The 
family caregiver, however, was fatigued by three months post 
tansplant, Iow family was defined in terms of sampled varied. 
None of the studies addresseed the impact on family when the 
adult member, undergoing transplant, died during or post trans- 
plantation. 
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BARRIERS TO SECOND TRANSPLANT FOR MULTIPLE MYELOMA IN A 
RANDOMIZED AUTOLOGOUS TANDEM TRIAL 
Wilson, R.L.; G~ay, M.L, Gir_alt, S. Blood and Mal~-ow Tr:aTz,rplanta- 
tio*~, Universi O, of Texas ~I.D> Anderson Cance'r Center, Hoztston, TX. 
The objective of this analysis is to identi .fy barriers to second 
transplant in multiple myeloma patients in a randomized tandem 
transplant setting. Patients were assessed from a current nmltiple 
myeloma trial at University of Texas M.D. Anderson Cancer Cen- 
ter. A total of 120 patients will be treated with an initial autolo- 
gous transplant. All patients are randomized prior to initial trans- 
plant to receive a 2nd autologous transplant with a different 
regime vs. ora] maintenance therapy if complete remission(OR) is
not achieved by day 180. Those patients that achieve CR are not 
eligible to receive the assigned treatment.To date, a total of 49 
patients have undergone initial transplant with 31 of those 
patients beyond 180 days post-initial transplant and cvaluable to 
receive the assigned treatment. Seventeen of the 31 were random- 
ized to the 2nd transplant and of theselT, 5 were in CR. The 
remaining 12 did not achieve CR and were eligible to receive the 
assigned 2nd transplant. Only 3 of the eligible 12 underwent sec- 
ond autologous transplantation.Reasons f r not proceeding with 
the planned treatment are as follows: 5 patients refused, 2 were 
denied by insurance coverage, and 2 were disqualified from study 
due to external factors. One patient was disqualified ue to inter- 
im treatment from the local physician. The final patient developed 
complications secondary to CMV pneumonia deeming him ineli- 
gible for second transplant.Regardless of the efforts made pre- 
transplant to educate the patient of the protocol requirements, 
one could speculate the reasons for patient refusal for the 2nd 
transplant. This might include length of time between transplants, 
~ime away from home, financial burden, poor initial transplant 
experience or differences between the two transplants, the 1st can 
be outpatient, and the 2nd is inpatient. Further analysis is war- 
ranted to investigate potential reasons for patient declination, 
which make up the majority of dais group at 55.56%. Insurance 
denials and disqualification account for 44.44% of non-2nd trans- 
plant participants.This analysis represents 25.83% of the total 
study population. 
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